Schizophrenia
Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.
What is Schizophrenia?
Schizophrenia is a chronic mental health disorder defined by episodes of psychosis, during which individuals experience hallucinations, delusions, and disorganised speech. It arises from a combination of genetic, neurobiological, and environmental factors, with structural abnormalities often observed in the prefrontal cortex and dopamine pathways.
The symptoms of schizophrenia are grouped into positive symptoms (hallucinations, delusions), negative symptoms (emotional blunting, lack of motivation), and cognitive symptoms (memory and concentration deficits). Diagnosis is based on the presence of these symptoms over a significant duration.
Neurobiological research implicates the serotonin system, particularly the 5-HT2A receptor, in the pathophysiology of schizophrenia, alongside disruptions in neurotransmitter systems like dopamine and glutamate.
Current Treatments
Standard treatment for schizophrenia involves antipsychotic medications, which primarily target dopamine pathways, often complemented by psychotherapy and social rehabilitation. However, these treatments frequently fail to adequately address negative and cognitive symptoms.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Schizophrenia.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Modern research supports psilocybin's role in enhancing neuroplasticity and connectivity which may potentially alleviate cognitive symptoms. | Medium | Moderate | Consistent |
| LSD Current studies explore LSD's neurobiological insights rather than therapeutic application due to the risk of exacerbating symptoms. | Medium | Moderate | Consistent |
| Ketamine Ketamine shows promise in quick relief of depressive symptoms and cognitive deficits in schizophrenia, supported by substantial clinical evidence. | Large | High | Consistent |
| MDMA MDMA's potential to enhance social engagement has been observed, but its therapeutic efficacy in schizophrenia is still under investigation. | Medium | Moderate | Inconsistent |
Ketamine and Schizophrenia
Ketamine, primarily an NMDA receptor antagonist, offers rapid relief from depressive symptoms and is being evaluated for its potential to address cognitive deficits in schizophrenia. Its unique mechanism differentiates it from classical psychedelics, thereby presenting both benefits and risks, including the possibility of exacerbating psychotic symptoms.
MDMA and Schizophrenia
MDMA has been investigated for its ability to improve emotional and social functioning, specifically targeting the negative symptoms of schizophrenia. Research indicates that, if administered in conjunction with therapy, MDMA may enhance emotional processing and reduce social withdrawal, yet its long-term safety and efficacy necessitate further study.
Key Insights
- 1
Early psychedelic studies highlighted the potential for classic hallucinogens to model psychosis, benefitting the understanding of schizophrenia’s neurobiology.
- 2
Modern research is investigating the utility of psychedelics as tools to inform the development of novel antipsychotic agents, rather than as direct treatments.
- 3
Psychological therapies combined with innovative compounds targeting different neurotransmitter systems are being explored to address treatment-resistant symptoms effectively.
Industrial Landscape
Key players in this field include Delix Therapeutics, MindMed, and Compass Pathways, which are exploring psychedelic-inspired compounds and non-hallucinogenic options aimed at improving cognitive and negative symptoms associated with schizophrenia.
Quick Indicators
\"Ongoing clinical evaluations are investigating Schizophrenia as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Schizophrenia.